

U.S. Patent Application Serial No. 10/768,193
Amendment filed May 22, 2007
Reply to OA dated February 23, 2007

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-2 (Canceled).

Claim 3 (Currently Amended): A recombinant [[An]] antibody having an activity of recognizing GM1 ganglioside-bound amyloid β -protein and inhibiting the formation of amyloid fibrils, the antibody being ~~is a recombinant~~ IgG, Fab, Fab', F(ab')₂, scFv, or dsFv, comprising: a heavy chain variable region, [[;]] and a light chain variable region, [[,]] wherein the heavy chain variable region comprises complementarity determining regions (CDRs) described in g), h) and i), and the light chain variable region comprises CDRs described in j), k) and l);

g) CDR 1 consisting of an amino acid sequence of SEQ ID NO. 1;

h) CDR 2 consisting of an amino acid sequence of SEQ ID NO. 2;

i) CDR 3 consisting of an amino acid sequence of SEQ ID NO. 3;

j) CDR 1 consisting of an amino acid sequence of SEQ ID NO. 4;

k) CDR 2 consisting of an amino acid sequence of SEQ ID NO. 5; and

l) CDR 3 consisting of an amino acid sequence of SEQ ID NO. 6.

U.S. Patent Application Serial No. **10/768,193**
Amendment filed **May 22, 2007**
Reply to OA dated February 23, 2007

Claim 4 (Previously Presented): The antibody according to claim 3, wherein the heavy chain variable region comprises an amino acid sequence of SEQ ID NO: 7.

Claim 5 (Previously Presented): The antibody according to claim 3, wherein the light chain variable region comprises an amino acid sequence of SEQ ID NO: 8.

Claim 6 (Previously Presented): The antibody according to claim 3, wherein the heavy chain variable region comprises an amino acid sequence of SEQ ID NO: 7; and the light chain variable region comprises an amino acid sequence of SEQ ID NO: 8.

Claim 7 (Previously Presented): The antibody according to claim 3, which is a humanized antibody.

Claims 8-31 (Canceled).